Meaningful Patient Engagement in Adolescent and Young Adult (AYA) Cancer Research: A Framework for Qualitative Studies
Curr Oncol. 2024 Mar 22;31(4):1689-1700. doi: 10.3390/curroncol31040128.ABSTRACTOver the last two decades, patient engagement in cancer research has evolved significantly, especially in addressing the unique challenges faced by adolescent and young adult (AYA) cancer populations. This paper introduces a framework for meaningful engagement with AYA cancer patient research partners, drawing insights from the "FUTURE" Study, a qualitative study that utilizes focus groups to explore the impact of cancer diagnosis and treatment on the sexual and reproductive health of AYA cancer patients in Canada. The framework's development i...
Source: Current Oncology - April 26, 2024 Category: Cancer & Oncology Authors: Niki Oveisi Vicki Cheng Dani Taylor Haydn Bechthold Mikaela Barnes Norman Jansen Helen McTaggart-Cowan Lori A Brotto Stuart Peacock Gillian E Hanley Sharlene Gill Meera Rayar Amirrtha Srikanthan Mary A De Vera Source Type: research
Soluble Immune Checkpoint Molecules as Predictors of Efficacy in Immuno-Oncology Combination Therapy in Advanced Renal Cell Carcinoma
In conclusion, sPD-L2 and sLAG-3 expression may serve as a potential biomarker for predicting IO combination therapy efficacy.PMID:38668032 | PMC:PMC11049572 | DOI:10.3390/curroncol31040129 (Source: Current Oncology)
Source: Current Oncology - April 26, 2024 Category: Cancer & Oncology Authors: Kosuke Ueda Keiichiro Uemura Naoki Ito Yuya Sakai Satoshi Ohnishi Hiroki Suekane Hirofumi Kurose Tasuku Hiroshige Katsuaki Chikui Kiyoaki Nishihara Makoto Nakiri Shigetaka Suekane Sachiko Ogasawara Hirohisa Yano Tsukasa Igawa Source Type: research
Complications and Recurrences after Excision and Reconstruction of Eyelid Tumours
CONCLUSIONS: The recurrence rate of eyelid tumours is lower than that of complications. The choice of surgical technique determines the frequency of complications and histological control of the excised tissue, as well as the frequency of recurrences.PMID:38668033 | PMC:PMC11049131 | DOI:10.3390/curroncol31040130 (Source: Current Oncology)
Source: Current Oncology - April 26, 2024 Category: Cancer & Oncology Authors: Georgi Balchev Source Type: research
Prognostic Factors Associated with Tumor Recurrence and Overall Survival in Soft Tissue Sarcomas of the Extremities in a Colombian Reference Cancer Center
Conclusions: This cohort showed that in addition to histologic grade and tumor size, tumor persistence at the time of admission has an impact on disease recurrence, so STS should be managed by a multidisciplinary team with experience in this pathology in high-volume reference centers.PMID:38668034 | PMC:PMC11049252 | DOI:10.3390/curroncol31040131 (Source: Current Oncology)
Source: Current Oncology - April 26, 2024 Category: Cancer & Oncology Authors: Sandra E D íaz Casas Juanita Mart ínez Villacrés Carlos Lehmann Mosquera Mauricio Garc ía Mora Iv án Mariño Lozano Javier Ángel Aristizábal Ra úl Suarez Rodríguez Carlos Alfonso Duarte Torres Ricardo S ánchez Pedraza Source Type: research
Prognosis versus Actual Outcomes in Stereotactic Radiosurgery of Brain Metastases: Reliability of Common Prognostic Parameters and Indices
This study aims to evaluate the clinical outcome of stereotactic radiosurgery as the sole treatment for brain metastases and to assess prognostic factors influencing survival. A total of 108 consecutive patients with 213 metastases were retrospectively analyzed. Treatment was determined with close-meshed MRI follow-up. Various prognostic factors were assessed, and several prognostic indices were compared regarding their reliability to estimate overall survival. Median overall survival was 15 months; one-year overall survival was 50.5%. Both one- and two-year local controls were 90.9%. The rate of new metastases after SRS w...
Source: Current Oncology - April 26, 2024 Category: Cancer & Oncology Authors: Julian Mangesius Thomas Seppi Christoph Reinhold Arnold Stephanie Mangesius Johannes Kerschbaumer Matthias Demetz Danijela Minasch Samuel Moritz Vorbach Manuel Sarcletti Peter Lukas Meinhard Nevinny-Stickel Ute Ganswindt Source Type: research
Deterioration of Performance Status during Palliative Radiotherapy Suggests a Significant Short Survival Duration: Indicating the Necessities for Considering Radiotherapy Discontinuation
This study aimed to investigate the survival duration of patients whose performance status (PS) deteriorated during palliative radiotherapy and inform decisions regarding early treatment discontinuation. We retrospectively analyzed data from patients referred from our institute's palliative care department who underwent ≥10 fractions of palliative radiotherapy between March 2017 and December 2021. PS was assessed using the Eastern Cooperative Oncology Group (ECOG) scale. Survival duration was calculated from the final day of palliative radiotherapy to death using the Kaplan-Meier method. A total of 35 patients underwent ...
Source: Current Oncology - April 26, 2024 Category: Cancer & Oncology Authors: Hitoshi Maemoto Kazuaki Kushi Isoko Owan Takuro Ariga Joichi Heianna Akihiro Nishie Source Type: research
Myelodysplastic Neoplasms (MDS) with Ring Sideroblasts or < em > SF3B1 < /em > Mutations: The Improved Clinical Utility of World Health Organization and International Consensus Classification 2022 Definitions, a Single-Centre Retrospective Chart Review
Curr Oncol. 2024 Mar 29;31(4):1762-1773. doi: 10.3390/curroncol31040134.ABSTRACTMyelodysplastic neoplasms (MDS) with ring sideroblasts (RS) are diagnosed via bone marrow aspiration in the presence of either (i) ≥15% RS or (ii) 5-14% RS and an SF3B1 mutation. In the MEDALIST trial and in an interim analysis of the COMMANDS trial, lower-risk MDS-RS patients had decreased transfusion dependency with luspatercept treatment. A total of 6817 patients with suspected hematologic malignancies underwent molecular testing using a next-generation-sequencing-based genetic assay and 395 MDS patients, seen at our centre from 1 January ...
Source: Current Oncology - April 26, 2024 Category: Cancer & Oncology Authors: Shamim Mortuza Benjamin Chin-Yee Tyler E James Ian H Chin-Yee Benjamin D Hedley Jenny M Ho Lalit Saini Alejandro Lazo-Langner Laila Schenkel Pratibha Bhai Bekim Sadikovic Jonathan Keow Nikhil Sangle Cyrus C Hsia Source Type: research
The Canadian Breast Cancer Symposium 2023 Meeting Report
Curr Oncol. 2024 Mar 29;31(4):1774-1802. doi: 10.3390/curroncol31040135.ABSTRACTOn 15-16 June 2023, healthcare professionals and breast cancer patients and advocates from across Canada met in Toronto, Ontario, for the 2023 Canadian Breast Cancer Symposium (CBSC.). The CBSC. is a national, multidisciplinary event that occurs every 2 years with the goal of developing a personalized approach to the management of breast cancer in Canada. Experts provided state-of-the-art information to help optimally manage breast cancer patients, including etiology, prevention, diagnosis, experimental biology, and therapy of breast cancer and...
Source: Current Oncology - April 26, 2024 Category: Cancer & Oncology Authors: Tulin Cil Jean-Fran çois Boileau Stephen Chia M J DeCoteau Katarzyna J Jerzak Anne Koch Nancy Nixon May Lynn Quan Amanda Roberts Christine Brezden-Masley Source Type: research
Access to Oncology Medicines in Canada: Consensus Forum for Recommendations for Improvement
Curr Oncol. 2024 Mar 29;31(4):1803-1816. doi: 10.3390/curroncol31040136.ABSTRACTPatient access to new oncology drugs in Canada is only possible after navigating multiple sequential systemic checkpoints for national regulatory approval, health technology assessment (HTA) and collective government price negotiation. These steps delay access and prevent health care providers from being able to prescribe optimal therapy. Eighteen Canadian oncology clinicians from the medicine, nursing and pharmacy professions met to develop consensus recommendations for defining reasonable government performance standards around process and ti...
Source: Current Oncology - April 26, 2024 Category: Cancer & Oncology Authors: Sandeep R Sehdev Nigel S B Rawson Olexiy I Aseyev Catriona J Buick Marcus O Butler Scott Edwards Sharlene Gill Joanna M Gotfrit Cyrus C Hsia Rosalyn A Juergens Mita Manna Joy S McCarthy Som D Mukherjee Stephanie L Snow Silvana Spadafora David J Stewart Ja Source Type: research
Large Language Models in Oncology: Revolution or Cause for Concern?
Curr Oncol. 2024 Mar 29;31(4):1817-1830. doi: 10.3390/curroncol31040137.ABSTRACTThe technological capability of artificial intelligence (AI) continues to advance with great strength. Recently, the release of large language models has taken the world by storm with concurrent excitement and concern. As a consequence of their impressive ability and versatility, their provide a potential opportunity for implementation in oncology. Areas of possible application include supporting clinical decision making, education, and contributing to cancer research. Despite the promises that these novel systems can offer, several limitations...
Source: Current Oncology - April 26, 2024 Category: Cancer & Oncology Authors: Aydin Caglayan Wojciech Slusarczyk Rukhshana Dina Rabbani Aruni Ghose Vasileios Papadopoulos Stergios Boussios Source Type: research
Successful Multimodal Treatment of Intracranial Growing Teratoma Syndrome with Malignant Features
Curr Oncol. 2024 Mar 29;31(4):1831-1838. doi: 10.3390/curroncol31040138.ABSTRACTMolecular analysis of the growing teratoma syndrome has not been extensively studied. Here, we report a 14-year-old boy with a growing mass during treatment for a mixed germ cell tumor of the pineal region. Tumor markers were negative; thus, growing teratoma syndrome was suspected. A radical resection via the occipital transtentorial approach was performed, and histopathological examination revealed a teratoma with malignant features. Methylation classifier analysis confirmed the diagnosis of teratoma, and DMRT1 loss and 12p gain were identifie...
Source: Current Oncology - April 26, 2024 Category: Cancer & Oncology Authors: Daiken Satake Manabu Natsumeda Kaishi Satomi Mari Tada Taro Sato Noritaka Okubo Keita Kawabe Haruhiko Takahashi Yoshihiro Tsukamoto Masayasu Okada Masakazu Sano Haruko Iwabuchi Nao Shibata Masaru Imamura Chihaya Imai Hirokazu Takami Koichi Ichimura Ryo Ni Source Type: research
Demographic Analysis of Cancer Research Priorities and Treatment Correlations
In conclusion, this study provides valuable insights into the complexity of cancer research priorities and treatment correlations in a European context. It emphasizes the importance of a multifaceted, patient-centred approach to cancer research and treatment, highlighting the need for ongoing support, adaptation, and collaboration to address the ever-changing landscape of oncology.PMID:38668042 | PMC:PMC11048756 | DOI:10.3390/curroncol31040139 (Source: Current Oncology)
Source: Current Oncology - April 26, 2024 Category: Cancer & Oncology Authors: Denis Horgan Marc Van den Bulcke Umberto Malapelle Nicola Normanno Ettore D Capoluongo Arsela Prelaj Carmelo Rizzari Aliki Stathopoulou Jaya Singh Marta Kozaric France Dube Manuel Ottaviano Stefania Boccia Gabriella Pravettoni Ivana Cattaneo N úria Malat Source Type: research
Exploration of Germline Correlates and Risk of Immune-Related Adverse Events in Advanced Cancer Patients Treated with Immune Checkpoint Inhibitors
Curr Oncol. 2024 Mar 30;31(4):1865-1875. doi: 10.3390/curroncol31040140.ABSTRACTImmune checkpoint inhibitors (ICIs) are increasingly used in the treatment of many tumor types, and durable responses can be observed in select populations. However, patients may exhibit significant immune-related adverse events (irAEs) that may lead to morbidity. There is limited information on whether the presence of specific germline mutations may highlight those at elevated risk of irAEs. We evaluated 117 patients with metastatic solid tumors or hematologic malignancies who underwent genomic analysis through the ongoing Personalized OncoGen...
Source: Current Oncology - April 26, 2024 Category: Cancer & Oncology Authors: Emma Titmuss Irene S Yu Erin D Pleasance Laura M Williamson Karen Mungall Andrew J Mungall Daniel J Renouf Richard Moore Steven J M Jones Marco A Marra Janessa J Laskin Kerry J Savage Source Type: research
Application of Multi-Criteria Decision Analysis (MCDA) to Prioritize Real-World Evidence Studies for Health Technology Management: Outcomes and Lessons Learned by the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration
Curr Oncol. 2024 Apr 1;31(4):1876-1898. doi: 10.3390/curroncol31040141.ABSTRACTMulti-criteria decision analysis (MCDA) is a value assessment tool designed to help support complex decision-making by incorporating multiple factors and perspectives in a transparent, structured approach. We developed an MCDA rating tool, consisting of seven criteria evaluating the importance and feasibility of conducting potential real-world evidence (RWE) studies aimed at addressing uncertainties stemming from initial cancer drug funding recommendations. In collaboration with the Canadian Agency for Drugs and Technologies in Health's Provinci...
Source: Current Oncology - April 26, 2024 Category: Cancer & Oncology Authors: Pam Takhar Marc Geirnaert Scott Gavura Jaclyn Beca Rebecca E Mercer Avram Denburg Caroline Mu ñoz Mina Tadrous Ambica Parmar Francois Dionne Darryl Boehm Carole Chambers Erica Craig Maureen Trudeau Matthew C Cheung Joanne Houlihan Valerie McDonald Petros Source Type: research
Radiological and Not Clinical Variables Guide the Surgical Plan in Patients with Glioblastoma
Conclusions: The volume of edema and proximity to the internal capsule were identified as independent factors associated with the surgical decision. The radiological evaluation and not the clinical situation of the patient influences the decision to perform a biopsy or CR.PMID:38668045 | PMC:PMC11049408 | DOI:10.3390/curroncol31040142 (Source: Current Oncology)
Source: Current Oncology - April 26, 2024 Category: Cancer & Oncology Authors: Carla Mart ín-Abreu Helga Fari ña-Jerónimo Julio Plata-Bello Source Type: research
